Epigenetics in Ovarian Cancer
Authors:
- 3 February 2012
- book chapter
- Published by Springer Nature
- Vol. 863, 253-269
Abstract
Ovarian cancer is the most lethal gynecological cancer. Due to few early symptoms and a lack of early detection strategies, most patients are diagnosed with advanced-stage disease. Most of these patients, although initially responsive, eventually develop drug resistance. In this chapter, epigenetic changes in ovarian cancer are described. Various epigenetic changes including CpG island methylation and histone modification have been identified in ovarian cancer. These aberrations are associated with distinct disease subtypes and present in circulating serum of ovarian cancer patients. Several epigenetic changes have shown promise for their diagnostic, prognostic, and predictive capacity but still need further validation. In contrast to DNA mutations and deletions, epigenetic modifications are potentially reversible by epigenetic therapies. Promising preclinical studies show epigenetic drugs to enhance gene re-expression and drug sensitivity in ovarian cancer cell lines and animal models.Keywords
This publication has 93 references indexed in Scilit:
- Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancerCancer, 2010
- Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancerLaboratory Investigation, 2010
- The context and potential of epigenetics in oncologyBritish Journal of Cancer, 2009
- Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancersMolecular Carcinogenesis, 2008
- Heparan sulphate synthetic and editing enzymes in ovarian cancerBritish Journal of Cancer, 2007
- The Epigenomics of CancerCell, 2007
- Clinical Evaluation of E-cadherin Expression and its Regulation Mechanism in Epithelial Ovarian CancerClinical & Experimental Metastasis, 2006
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- Initial sequencing and analysis of the human genomeNature, 2001